Condition: Locally Advanced Pancreatic Cancer · Borderline Resectable Pancreatic Cancer · Pancreatectomy · Sponsor: Oslo University Hospital
NORPACT-3 is a nationwide, Norwegian single arm prospective study that evaluates the resectability rates and survival in patients with borderline resectable and locally advanced pancreatic cancer who received primary chemotherapy. Eligible patients are treated with primary chemotherapy possibly followed by surgical exploration and resection. All Norwegian centres performing pancreatic surgery have agreed to collaborate in this trial. The assignment of the medical intervention is not at the discretion of the investigator, but follow the national Norwegian guidelines regarding diagnostic work up, oncological and surgical treatment and follow up. The primary aim is a national resection rate of 50% in BRPC and 15% in LAPC in patients initiating primary chemotherapy, with adequate overall survival and morbidity/mortality (after resection median overall survival of 24 months, 1 year survival 80%, and 5 year survival \>20% + 90 day postoperative mortality ≤5%, 90-day postoperative major morbidity (Clavien Dindo grade 3) ≤40%).
This description comes directly from the study's public registry record.
Knut Jørgen Labori, MD PhD · +4723070000 · uxknab@ous-hf.no
Jacob Ghotbi, MD · +4723070000 · Jacob.Ghotbi@ous-hf.no
Always discuss trial participation with your own doctor first.
| Haukeland University Hospital | Bergen, Norway, Norway | Not Yet Recruiting |
| Stavanger University Hospital | Stavanger, Norway, Norway | Not Yet Recruiting |
| University Hospital of North Norway | Tromsø, Norway, Norway | Not Yet Recruiting |
| St. Olavs Hospital, Trondheim University Hospital | Trondheim, Norway, Norway | Not Yet Recruiting |
| Oslo University Hospital | Oslo, Norway | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06944587